<DOC>
	<DOC>NCT01340053</DOC>
	<brief_summary>This is a multi-center, Phase 2, randomized, double-blind, placebo controlled study of RDX5791 in subjects with IBS-C. Patients who are 18 to 75 years old, meeting the definition of IBS-C as defined by the Rome III Criteria for the Diagnosis of IBS will undergo a battery of screening procedures to determine eligibility for the trial. The study will consist of a 2-week treatment-free screening period, a 4-week blinded treatment period, and a 2-week treatment-free follow-up period.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Subject meets Rome III criteria for IBSC If &gt; 50 years old, colonoscopy evaluation within 10 years All ages, negative colonoscopy if any "warning symptoms" Active disease during 2week screening period Compliant with IVRS Subjects has IBSD, IBSM or unsubtyped IBS according to Rome III criteria Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract Use of medications that are known to affect stool consistency Subject has any protocolexcluded or clinically significant medical or surgical history that could confound the study assessments or prevent completion of study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>